Cargando…

Engaging Cytotoxic T and NK Cells for Immunotherapy in Chronic Lymphocytic Leukemia

Chronic lymphocytic leukemia (CLL) is characterized by an acquired immune dysfunction. CLL cells affect the phenotype and function of the entire spectrum of innate and adaptive immune cells, including monocytes, T cells, and natural killer (NK) cells, leading to a tumor-supportive environment and re...

Descripción completa

Detalles Bibliográficos
Autores principales:	Hofland, Tom, Eldering, Eric, Kater, Arnon P., Tonino, Sanne H.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2019
Materias:	Review
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6747204/ https://www.ncbi.nlm.nih.gov/pubmed/31484424 http://dx.doi.org/10.3390/ijms20174315

Ejemplares similares

Natural Killer Cell Hypo-responsiveness in Chronic Lymphocytic Leukemia can be Circumvented In Vitro by Adequate Activating Signaling
por: Hofland, Tom, et al.
Publicado: (2019)

Proliferative Signals in Chronic Lymphocytic Leukemia; What Are We Missing?
por: Haselager, Marco V., et al.
Publicado: (2020)

Chronic lymphocytic leukemia cells are active participants in microenvironmental cross-talk
por: van Attekum, Martijn HA, et al.
Publicado: (2017)

T-cell dysfunction in chronic lymphocytic leukemia from an epigenetic perspective
por: Peters, Fleur S., et al.
Publicado: (2021)

P593: T-CELL DYSFUNCTION BY PSEUDOHYPOXIA AND AUTOCRINE PURINERGIC SIGNALING IN CHRONIC LYMPHOCYTIC LEUKEMIA
por: Montironi, Chiara, et al.
Publicado: (2023)

T-cell dysfunction by pseudohypoxia and autocrine purinergic signaling in chronic lymphocytic leukemia
por: Montironi, Chiara, et al.
Publicado: (2023)

P595: DEFECTIVE MITOCHONDRIAL METABOLISM IS AT THE BASIS OF T-CELL DYSFUNCTION IN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Simon-Molas, Helga, et al.
Publicado: (2023)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

CD3xCD19 DART molecule treatment induces non-apoptotic killing and is efficient against high-risk chemotherapy and venetoclax-resistant chronic lymphocytic leukemia cells
por: Martens, Anne W J, et al.
Publicado: (2020)

Co-Stimulatory versus Cell Death Aspects of Agonistic CD40 Monoclonal Antibody Selicrelumab in Chronic Lymphocytic Leukemia
por: Delgado, Raquel, et al.
Publicado: (2021)

Macrophage-mediated chronic lymphocytic leukemia cell survival is independent of APRIL signaling
por: van Attekum, MHA, et al.
Publicado: (2016)

CD40 signaling instructs chronic lymphocytic leukemia cells to attract monocytes via the CCR2 axis
por: van Attekum, Martijn H.A., et al.
Publicado: (2017)

Current state of NK cell-mediated immunotherapy in chronic lymphocytic leukemia
por: Wang, Zong-Han, et al.
Publicado: (2023)

Combining novel agents in chronic lymphocytic leukemia: Greater than the sum of its parts?
por: de Weerdt, Iris, et al.
Publicado: (2019)

Human CXCR5(+)PD‐1(+) CD8 T cells in healthy individuals and patients with hematologic malignancies
por: Hofland, Tom, et al.
Publicado: (2020)

Kinase inhibitors developed for treatment of hematologic malignancies: implications for immune modulation in COVID-19
por: Jacobs, Chaja F., et al.
Publicado: (2021)

Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features
por: van der Straten, Lina, et al.
Publicado: (2021)

Cytogenetics in Chronic Lymphocytic Leukemia: ERIC Perspectives and Recommendations
por: Baliakas, Panagiotis, et al.
Publicado: (2022)

Chronic lymphocytic leukemia presence impairs antigen-specific CD8(+) T-cell responses through epigenetic reprogramming towards short-lived effectors
por: Martens, Anne W. J., et al.
Publicado: (2023)

NK Cells in Chronic Lymphocytic Leukemia and Their Therapeutic Implications
por: Sportoletti, Paolo, et al.
Publicado: (2021)

Macrophages confer survival signals via CCR1-dependent translational MCL-1 induction in chronic lymphocytic leukemia
por: van Attekum, M H A, et al.
Publicado: (2017)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

Functional Differences Between EBV- and CMV-Specific CD8(+) T cells Demonstrate Heterogeneity of T cell Dysfunction in CLL
por: Hofland, Tom, et al.
Publicado: (2020)

Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma
por: van Bruggen, Jaco A. C., et al.
Publicado: (2020)

Correction: van Bruggen et al. Overcoming the Hurdles of Autologous T-Cell-Based Therapies in B-Cell Non-Hodgkin Lymphoma. Cancers 2020, 12, 3837
por: van Bruggen, Jaco A. C., et al.
Publicado: (2021)

T Cell Defects and Immunotherapy in Chronic Lymphocytic Leukemia
por: Vlachonikola, Elisavet, et al.
Publicado: (2021)

Redirecting T-cell Activity with Anti-BCMA/Anti-CD3 Bispecific Antibodies in Chronic Lymphocytic Leukemia and Other B-cell Lymphomas
por: Martens, Anne W.J., et al.
Publicado: (2022)

Expanded and activated allogeneic NK cells are cytotoxic against B-chronic lymphocytic leukemia (B-CLL) cells with sporadic cases of resistance
por: Calvo, Tania, et al.
Publicado: (2020)

Enhancing Neuroblastoma Immunotherapies by Engaging iNKT and NK Cells
por: McNerney, Kevin O., et al.
Publicado: (2020)

A mutated B cell chronic lymphocytic leukemia subset that recognizes and responds to fungi
por: Hoogeboom, Robbert, et al.
Publicado: (2013)

Assessment of p53 and ATM functionality in chronic lymphocytic leukemia by multiplex ligation-dependent probe amplification
por: te Raa, G D, et al.
Publicado: (2015)

A case report of extranodal NK/T-cell lymphoma in patient with chronic lymphocytic leukemia
por: Ge, Hangping, et al.
Publicado: (2018)

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
por: Sharman, Jeffrey P., et al.
Publicado: (2022)

BTLA/HVEM Axis Induces NK Cell Immunosuppression and Poor Outcome in Chronic Lymphocytic Leukemia
por: Sordo-Bahamonde, Christian, et al.
Publicado: (2021)

NK Cell-Mediated Antibody-Dependent Cellular Cytotoxicity in Cancer Immunotherapy
por: Wang, Wei, et al.
Publicado: (2015)

Targeting cytotoxic T lymphocytes for cancer immunotherapy
por: Maher, J, et al.
Publicado: (2004)

CD8(+) T Lymphocyte and NK Cell Network: Circuitry in the Cytotoxic Domain of Immunity
por: Uzhachenko, Roman V., et al.
Publicado: (2019)

NK Cells and Other Cytotoxic Innate Lymphocytes in Colorectal Cancer Progression and Metastasis
por: Fionda, Cinzia, et al.
Publicado: (2022)

Risk of second primary malignancies in patients with chronic lymphocytic leukemia: a population-based study in the Netherlands, 1989-2019
por: van der Straten, Lina, et al.
Publicado: (2023)

Chemo-immunotherapy for Older Patients with Chronic Lymphocytic Leukemia – Time to Retire?
por: Scarfò, Lydia, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_ikjjl1p4bm0auudim7kj3512r2